Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AORT Artivion Inc
- Stocks
- Healthcare
- NYSE: AORT
Price (delayed)
$31.19
Market cap
$1.33B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.5
Enterprise value
$1.66B
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins
Highlights
Artivion's equity has increased by 7% QoQ
The company's revenue rose by 6% YoY
AORT's quick ratio is up by 23% since the previous quarter but it is down by 8% year-on-year
The net income has plunged by 122% YoY and by 60% from the previous quarter
Artivion's EPS has shrunk by 108% YoY and by 56% QoQ
Key stats
What are the main financial stats of AORT
Market
Valuations
Earnings
Shares outstanding
42.7M
Market cap
$1.33B
Enterprise value
$1.66B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.46
Price to sales (P/S)
3.38
EV/EBIT
143.75
EV/EBITDA
41.95
EV/Sales
4.25
Revenue
$390.08M
Gross profit
$249.41M
Operating income
$15.71M
Net income
-$21.4M
EBIT
$11.52M
EBITDA
$39.49M
Free cash flow
-$439,000
Per share
Balance sheet
Liquidity
EPS
-$0.5
EPS diluted
-$0.5
Free cash flow per share
-$0.01
Book value per share
$7
Revenue per share
$9.24
TBVPS
$9.24
Total assets
$791.16M
Total liabilities
$496.91M
Debt
$362.36M
Equity
$294.25M
Working capital
$235.36M
Debt to equity
1.23
Current ratio
5.53
Quick ratio
2.57
Net debt/EBITDA
8.22
Margins
Efficiency
Dividend
EBITDA margin
10.1%
Gross margin
63.9%
Net margin
-5.5%
Operating margin
4%
Return on assets
-2.7%
Return on equity
-7.3%
Return on invested capital
1.9%
Return on capital employed
1.6%
Return on sales
3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AORT stock price
How has the Artivion stock price performed over time
Intraday
1.86%
1 week
3.11%
1 month
6.78%
1 year
25.51%
YTD
9.09%
QTD
26.89%
Financial performance
How have Artivion's revenue and profit performed over time
Revenue
$390.08M
Gross profit
$249.41M
Operating income
$15.71M
Net income
-$21.4M
Gross margin
63.9%
Net margin
-5.5%
The net income has plunged by 122% YoY and by 60% from the previous quarter
AORT's net margin has dropped by 112% year-on-year and by 62% since the previous quarter
The operating margin has dropped by 60% since the previous quarter and by 29% year-on-year
The company's operating income has shrunk by 60% QoQ and by 24% YoY
Price vs fundamentals
How does AORT's price correlate with its fundamentals
Growth
What is Artivion's growth rate over time
Valuation
What is Artivion stock price valuation
P/E
N/A
P/B
4.46
P/S
3.38
EV/EBIT
143.75
EV/EBITDA
41.95
EV/Sales
4.25
Artivion's EPS has shrunk by 108% YoY and by 56% QoQ
The stock's price to book (P/B) is 59% more than its 5-year quarterly average of 2.8 and 17% more than its last 4 quarters average of 3.8
Artivion's equity has increased by 7% QoQ
The price to sales (P/S) is 30% higher than the 5-year quarterly average of 2.6 and 17% higher than the last 4 quarters average of 2.9
The company's revenue rose by 6% YoY
Efficiency
How efficient is Artivion business performance
AORT's return on assets has dropped by 125% year-on-year and by 59% since the previous quarter
AORT's ROE has shrunk by 115% YoY and by 59% QoQ
Artivion's return on sales has shrunk by 59% YoY and by 57% QoQ
The ROIC has shrunk by 57% QoQ and by 57% YoY
Dividends
What is AORT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Artivion financials performed over time
The total assets is 59% greater than the total liabilities
AORT's current ratio is up by 27% since the previous quarter but it is down by 8% year-on-year
AORT's quick ratio is up by 23% since the previous quarter but it is down by 8% year-on-year
AORT's debt is 23% greater than its equity
Artivion's equity has increased by 7% QoQ
The debt to equity has contracted by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.